Timothy J. Scannell left the role of Director at Insulet Corp, effective September 3, 2026. As of November 6, 2026, Insulet Corp has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from June 25, 2026 to September 16, 2026, naming 1 appointment and 1 departure (Form 8-K, September 10, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Insulet Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-09-16
- · In / out: Out · Person: Timothy J. Scannell · Role: Director · Effective: 2026-09-03 · 8-K, 2026-09-10
- · In / out: In · Person: Jonathan J. Mazelsky · Role: Director · Effective: 2026-07-01 · 8-K, 2026-06-25
Insulet Corp reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-06-25 to 2026-09-16. They name 2 people, with 1 appointment and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Insulet Corp files it.
Also on the record for Insulet Corp
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 27, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 7.7% of the class | 5%+ stakes | Source |
| August 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 1.4% of the class | 5%+ stakes | Source |
| May 14, 2026 | Stake report, Schedule 13G/A, by Capital Research Global Investors | 2.4% of the class | 5%+ stakes | Source |
| May 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 5.6% of the class | 5%+ stakes | Source |
| April 30, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 7.49% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 5, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 9% of the class | 5%+ stakes | Source |
| October 30, 2025 | Stake report, Schedule 13G/A, by The Vanguard Group | 12.49% of the class | 5%+ stakes | Source |
| August 13, 2025 | Stake report, Schedule 13G/A, by Capital Research Global Investors | 6.7% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Insulet Corp now and the warning signs.
Free to see. No signup.
Keep reading
More on Insulet Corp and the records around it.
Insulet Corp elsewhere on the record
Companies that share a holder
- Capital Research Global Investors also filed stake reports on 99 other companies: Royal Caribbean Cruises Ltd. (Oct 2026), Patria Investments Ltd. (Sep 2026), Arxis, Inc. (Aug 2026)
- FMR LLC also filed stake reports on 761 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
- Vanguard Capital Management also filed stake reports on 1495 other companies: A10 Networks Inc (Oct 2026), Altisource Portfolio Solutions SA (Oct 2026), Alto Neuroscience Inc (Oct 2026)
Watch Insulet Corp
Get an email when Insulet Corp files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Insulet Corp?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Insulet Corp: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Insulet Corp covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-16 | Reported | not named in the filing | 8-K, 2026-09-16 | ||
| 2026-09-10 | Out | Director | 2026-09-03 | 8-K, 2026-09-10 | |
| 2026-06-25 | In | Director | 2026-07-01 | 8-K, 2026-06-25 |
Who leads Insulet Corp, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Timothy J. Scannell, departure reported, effective 2026-09-03 (filed 2026-09-10). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Insulet Corp: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Insulet Corp, with the record behind each one.
Find candidates like Director at Insulet CorpEvery change, in the filing's words
Reported
The Committee may, at any time, in its sole discretion, terminate the Plan or amend or modify the Plan, in whole or in part, except that no such amendment or modification shall deprive any participant or beneficiary of any right or benefit under any account to which such participant or beneficiary is entitled immediately prior to the effective date of the amendment.
- Adoption of Nonqualified Deferred Compensation Plan On September 14, 2026, the Talent and Compensation Committee (the "Committee") of the Board of Directors (the "Board") of Insulet Corporation (the "Company") approved and adopted the Insulet Nonqualified Deferred Compensation Plan (the "Plan"), with such Plan to be effective on January 1, 2027.
- The Plan is intended to be an unfunded "top hat" deferred compensation plan that allows a select group of management or highly compensated employees within the meaning of the Employee Retirement Income Security Act of 1974, as amended ("ERISA"), including the Company's named executive officers, to voluntarily defer compensation in a manner intended to comply with Section 409A of the Internal Revenue Code of 1986, as amended (the "Code").
- The Plan will be administered by the Company's Employee Benefits Committee or such other administrative committee as the Committee may designate.
- Participants in the Plan are designated by the Committee and may elect to defer up to 60% of their cash compensation, consisting of base salary, annual incentive bonus and such other cash compensation as the Committee may approve.
- All participant cash deferrals and related earnings will be fully vested under the Plan.
- Equity awards may not be deferred under the Plan.
Departing: Timothy J. Scannell, Director, effective 2026-09-03
On September 3, 2026, Timothy J. Scannell, a member of the Board of Directors (the "Board") of Insulet Corporation (the "Company"), notified the Company of his decision to step down from the Board for health reasons, effective September 3, 2026.
- The Board and management extend their sincere appreciation to Mr. Scannell for his leadership, unwavering commitment and invaluable guidance to the Company throughout his 12 years of service on the Board, including 7 years as Chairman of the Board, during which he helped guide the Company through a period of significant growth and advancement.
- On September 8, 2026, Michael R. Minogue also notified the Company of his decision to step down from the Board to focus on his candidacy for Governor of Massachusetts, effective September 15, 2026.
- The Board and management are grateful to Mr. Minogue for his leadership, dedication and passion during his 9 years of distinguished service to the Company and the Board.
- Neither Mr. Scannell nor Mr. Minogue resigned due to any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
Appointed: Jonathan J. Mazelsky, Director, effective 2026-07-01
On June 24, 2026, the Board of Directors (the "Board") of Insulet Corporation (the "Company") appointed Jonathan J. Mazelsky as a Class II director, effective July 1, 2026.
- Mr. Mazelsky will stand for election by stockholders at the Company's 2027 Annual Meeting of Stockholders.
- Mr. Mazelsky has been the Executive Chair of the board of directors of IDEXX Laboratories, Inc. since May 2026.
- He also served at IDEXX as President and Chief Executive Officer from October 2019 to May 2026, as Interim President and Chief Executive Officer from June 2019 to October 2019, and as Executive Vice President responsible for IDEXX's North American Companion Animal Group Commercial Organization and key elements of their innovation portfolio from August 2012 to June 2019.
- From 2010 to 2012, he served as Senior Vice President and General Manager, Computed Tomography, Nuclear Medicine and Radiation Therapy Planning at Philips Healthcare, a subsidiary of Royal Philips Electronics (now named Royal Philips), where he also held roles of increasing responsibility from 2001 to 2010.
- Prior to joining Philips, Mr. Mazelsky was at Agilent Technologies, where he was an Executive in Charge from 2000 to 2002, leading the integration of Agilent's Healthcare Group into Philips, and General Manager of Agilent's Medical Consumables Business Unit from 1997 to 2000.
- From 1988 to 1996, Mr. Mazelsky held a number of roles at Hewlett Packard in finance, marketing and business planning.
Tools for this story
Each opens in a new tab, filled in for Insulet Corp. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.